Sanofi has scored FDA approval for its subcutaneous version of Sarclisa, giving the multiple myeloma treatment a potential ...

By Sneha S K and Bhanvi Satija July 10 (Reuters) - The U.S. Food and Drug Administration said on Friday it has approved a ...

Sanofi (SNY) wins FDA approval for Sarclisa Escena, a subcutaneously-delivered version of its multiple myeloma therapy ...

Hansen, MD, discusses outcomes from a large retrospective study of patients treated with ciltacabtagene autoleucel for ...

Johnson & Johnson JNJ announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use ...

Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in diagnostic and prognostic innovation through advanced telomere analytics, today announced that it has filed a U.S ...

Regulatory clearance adds a 1,400-mg subcutaneous CD38 antibody option using CirCLIQ on-body delivery or provider-administered injection, maintaining the same active medicine as the IV formulation.

Rahul Banerjee, MD, discusses the most relevant multiple myeloma treatment options presented at the EHA Congress 2026.

Multiple myeloma is a type of blood cancer that starts in your bone marrow. This is the soft, spongy tissue inside your bones that makes most of your blood cells. It includes plasma cells, which help ...

MULTIPLE myeloma ICU survival has improved in recent years, with better adjusted one year outcomes despite greater illness ...

Pfizer’s MUltiple Myeloma Italian ObServational sTudy (MUST) looks at how Italian centers treat patients with triple class refractory multiple myeloma, a hard‑to‑treat blood cancer. The study tracks ...

Neither Rick Letterman nor Jeff Main had symptoms when routine bloodwork revealed they had multiple myeloma, a rare blood ...